Literature DB >> 15858000

Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins.

Andrea Bertolotti-Ciarlet1, Jonathan Smith, Karin Strecker, Jason Paragas, Louis A Altamura, Jeanne M McFalls, Natalia Frias-Stäheli, Adolfo García-Sastre, Connie S Schmaljohn, Robert W Doms.   

Abstract

Crimean-Congo hemorrhagic fever virus (CCHFV), a member of the genus Nairovirus of the family Bunyaviridae, causes severe disease with high rates of mortality in humans. The CCHFV M RNA segment encodes the virus glycoproteins G(N) and G(C). To understand the processing and intracellular localization of the CCHFV glycoproteins as well as their neutralization and protection determinants, we produced and characterized monoclonal antibodies (MAbs) specific for both G(N) and G(C). Using these MAbs, we found that G(N) predominantly colocalized with a Golgi marker when expressed alone or with G(C), while G(C) was transported to the Golgi apparatus only in the presence of G(N). Both proteins remained endo-beta-N-acetylglucosaminidase H sensitive, indicating that the CCHFV glycoproteins are most likely targeted to the cis Golgi apparatus. Golgi targeting information partly resides within the G(N) ectodomain, because a soluble version of G(N) lacking its transmembrane and cytoplasmic domains also localized to the Golgi apparatus. Coexpression of soluble versions of G(N) and G(C) also resulted in localization of soluble G(C) to the Golgi apparatus, indicating that the ectodomains of these proteins are sufficient for the interactions needed for Golgi targeting. Finally, the mucin-like and P35 domains, located at the N terminus of the G(N) precursor protein and removed posttranslationally by endoproteolysis, were required for Golgi targeting of G(N) when it was expressed alone but were dispensable when G(C) was coexpressed. In neutralization assays on SW-13 cells, MAbs to G(C), but not to G(N), prevented CCHFV infection. However, only a subset of G(C) MAbs protected mice in passive-immunization experiments, while some nonneutralizing G(N) MAbs efficiently protected animals from a lethal CCHFV challenge. Thus, neutralization of CCHFV likely depends not only on the properties of the antibody, but on host cell factors as well. In addition, nonneutralizing antibody-dependent mechanisms, such as antibody-dependent cell-mediated cytotoxicity, may be involved in the in vivo protection seen with the MAbs to G(C).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858000      PMCID: PMC1091677          DOI: 10.1128/JVI.79.10.6152-6161.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  A signal for Golgi retention in the bunyavirus G1 glycoprotein.

Authors:  Y Matsuoka; S Y Chen; R W Compans
Journal:  J Biol Chem       Date:  1994-09-09       Impact factor: 5.157

2.  Enhanced neutralization of La Crosse virus by the binding of specific pairs of monoclonal antibodies to the G1 glycoprotein.

Authors:  L Kingsford
Journal:  Virology       Date:  1984-07-30       Impact factor: 3.616

3.  La Crosse virus G1 glycoprotein undergoes a conformational change at the pH of fusion.

Authors:  F Gonzalez-Scarano
Journal:  Virology       Date:  1985-01-30       Impact factor: 3.616

4.  An avirulent G1 glycoprotein variant of La Crosse bunyavirus with defective fusion function.

Authors:  F Gonzalez-Scarano; R S Janssen; J A Najjar; N Pobjecky; N Nathanson
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

5.  Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor.

Authors:  W A Alexander; B Moss; T R Fuerst
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  The Hantaan virus M-segment glycoproteins G1 and G2 can be expressed independently.

Authors:  M N Pensiero; J Hay
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  Optimizing hydrolysis of N-linked high-mannose oligosaccharides by endo-beta-N-acetylglucosaminidase H.

Authors:  R B Trimble; F Maley
Journal:  Anal Biochem       Date:  1984-09       Impact factor: 3.365

8.  Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies.

Authors:  J Arikawa; J S Yao; K Yoshimatsu; I Takashima; N Hashimoto
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

9.  Expression of the Bunyamwera virus M genome segment and intracellular localization of NSm.

Authors:  G W Nakitare; R M Elliott
Journal:  Virology       Date:  1993-08       Impact factor: 3.616

10.  Monoclonal antibodies directed against the envelope glycoproteins of La Crosse virus.

Authors:  G V Ludwig; B A Israel; B M Christensen; T M Yuill; K T Schultz
Journal:  Microb Pathog       Date:  1991-12       Impact factor: 3.738

View more
  57 in total

1.  Crimean-Congo hemorrhagic fever virus genomics and global diversity.

Authors:  Varough M Deyde; Marina L Khristova; Pierre E Rollin; Thomas G Ksiazek; Stuart T Nichol
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus.

Authors:  S M Ghiasi; A H Salmanian; S Chinikar; S Zakeri
Journal:  Clin Vaccine Immunol       Date:  2011-10-19

3.  Identification of a putative Crimean-Congo hemorrhagic fever virus entry factor.

Authors:  Xiaodong Xiao; Yang Feng; Zhongyu Zhu; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2011-06-23       Impact factor: 3.575

4.  Crimean-Congo Hemorrhagic Fever Mouse Model Recapitulating Human Convalescence.

Authors:  David W Hawman; Kimberly Meade-White; Elaine Haddock; Rumi Habib; Dana Scott; Tina Thomas; Rebecca Rosenke; Heinz Feldmann
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

5.  Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus.

Authors:  Marko Zivcec; Lisa I W Guerrero; César G Albariño; Éric Bergeron; Stuart T Nichol; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2017-08-24       Impact factor: 5.970

6.  Mutagenesis of the La Crosse Virus glycoprotein supports a role for Gc (1066-1087) as the fusion peptide.

Authors:  Matthew L Plassmeyer; Samantha S Soldan; Karen M Stachelek; Susan M Roth; Julio Martín-García; Francisco González-Scarano
Journal:  Virology       Date:  2006-10-05       Impact factor: 3.616

7.  Therapeutic intervention in Crimean-Congo hemorrhagic fever: where are we now?

Authors:  Jessica R Spengler; Dennis A Bente
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

Review 8.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

9.  Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein.

Authors:  Louis A Altamura; Andrea Bertolotti-Ciarlet; Jeffrey Teigler; Jason Paragas; Connie S Schmaljohn; Robert W Doms
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

10.  Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice.

Authors:  Jeroen Kortekaas; Rianka P M Vloet; Alexander J McAuley; Xiaoli Shen; Berend Jan Bosch; Laura de Vries; Rob J M Moormann; Dennis A Bente
Journal:  Vector Borne Zoonotic Dis       Date:  2015-12       Impact factor: 2.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.